Core Insights - ORIC Pharmaceuticals presented promising preclinical data for ORIC-944, a selective allosteric inhibitor of PRC2, at the 2025 EORTC-NCI-AACR conference, indicating its potential in treating prostate cancer and other solid tumors [1][2] Group 1: ORIC-944 Overview - ORIC-944 is characterized as a potent and selective allosteric PRC2 inhibitor, demonstrating best-in-class drug properties in preclinical studies, including favorable pharmacokinetics and a clinical half-life of approximately 20 hours [4][5] - The drug has shown positive interim PSA response data in ongoing Phase 1b trials, both as a single agent and in combination with other treatments for prostate cancer [4][5] Group 2: Mechanism and Efficacy - PRC2 inhibition has been shown to enhance the response to AR inhibitors, delaying treatment relapse in castration-sensitive prostate cancer by restricting tumor cell adaptation [3][5] - In preclinical models, ORIC-944 combined with KRAS inhibitors significantly improved efficacy and progression-free survival in KRAS G12C mutant non-small cell lung cancer and colorectal cancer, indicating its ability to prevent or delay resistance [5] Group 3: Clinical Development and Future Potential - The company continues to believe that ORIC-944 has the potential to be a best-in-class PRC2 inhibitor, with applications in both castration-resistant and castration-sensitive prostate cancer, as well as other tumor types [2][5] - ORIC Pharmaceuticals is dedicated to overcoming resistance in cancer, with ORIC-944 being a key candidate in their clinical stage pipeline [6]

As filed with the Securities and Exchange Commission on August 26, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Silexion Therapeutics Corp (Exact name of registrant as specified in its charter) Cayman Islands 8731 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 12 Abba Hillel ...